Literature DB >> 1375198

Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection.

J S Friedland1, Y Suputtamongkol, D G Remick, W Chaowagul, R M Strieter, S L Kunkel, N J White, G E Griffin.   

Abstract

Patients suffering from serious bacterial infection present to the hospital after early inflammatory events, such as release of tumor necrosis factor (TNF), have been initiated. The role of other cytokines, such as interleukin-8 (IL-8), a neutrophil chemoattractant and activator, in the pathophysiology of human sepsis is not well characterized, and there are only limited data on IL-6. We studied serial concentrations of TNF, IL-6 (involved in the acute-phase response), and IL-8 in plasma and leukocyte levels of mRNA for these cytokines in patients with localized and septicemic Pseudomonas pseudomallei infection on admission to the hospital and during a prolonged recovery phase (up to 30 days). Of 18 patients, 8 had detectable plasma IL-8 and all had raised plasma IL-6 concentrations. In patients who died median initial concentration of IL-8 (167 pg/ml; range, 97 to 362 pg/ml) and IL-6 (4,800 pg/ml; range, 60 to 9,245 pg/ml) in plasma were higher than those in survivors (P less than 0.008 and P = 0.007, respectively). Septic patients who survived and patients with localized disease had similar cytokine levels. Plasma IL-8 and IL-6 concentrations were elevated throughout the inpatient period of recovery. Circulating leukocytes contained mRNA for IL-8 but not for IL-6 and TNF, and they may secrete IL-8. An elevated plasma IL-6 concentration (greater than 1,000 pg/ml) had 75% mortality) was the best predictor of mortality in P. pseudomallei sepsis. Fifty percent of patients with detectable plasma IL-8 concentrations died. In contrast, plasma TNF bioactivity did not relate to outcome; 75% of patients who did never had detectable plasma TNF activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375198      PMCID: PMC257173          DOI: 10.1128/iai.60.6.2402-2408.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6.

Authors:  T R Ulich; K Z Guo; D Remick; J del Castillo; S M Yin
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

2.  Oxpentifylline in endotoxaemia.

Authors:  P Zabel; D T Wolter; M M Schönharting; U F Schade
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

3.  IFN-beta 2/IL-6 augments the activity of human natural killer cells.

Authors:  T A Luger; J Krutmann; R Kirnbauer; A Urbanski; T Schwarz; G Klappacher; A Köck; M Micksche; J Malejczyk; E Schauer
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

4.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

5.  IL-8 in septic shock, endotoxemia, and after IL-1 administration.

Authors:  K J Van Zee; L E DeForge; E Fischer; M A Marano; J S Kenney; D G Remick; S F Lowry; L L Moldawer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

6.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever.

Authors:  J G Cannon; R G Tompkins; J A Gelfand; H R Michie; G G Stanford; J W van der Meer; S Endres; G Lonnemann; J Corsetti; B Chernow
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

7.  Tumor necrosis factor-independent IL-6 production during murine listeriosis.

Authors:  E A Havell; P B Sehgal
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

8.  Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions.

Authors:  M A Gimbrone; M S Obin; A F Brock; E A Luis; P E Hass; C A Hébert; Y K Yip; D W Leung; D G Lowe; W J Kohr
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

9.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans.

Authors:  P Damas; A Reuter; P Gysen; J Demonty; M Lamy; P Franchimont
Journal:  Crit Care Med       Date:  1989-10       Impact factor: 7.598

10.  Monokine-induced neutrophil chemotactic factor gene expression in human fibroblasts.

Authors:  R M Strieter; S H Phan; H J Showell; D G Remick; J P Lynch; M Genord; C Raiford; M Eskandari; R M Marks; S L Kunkel
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

View more
  43 in total

Review 1.  Time course of cytokine levels in sepsis.

Authors:  L G Thijs; C E Hack
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

2.  Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity.

Authors:  Jodie Morris; Natasha Williams; Catherine Rush; Brenda Govan; Kunwarjit Sangla; Robert Norton; Natkunam Ketheesan
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

3.  Tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion and the acute-phase response in patients with bacterial and tuberculous osteomyelitis.

Authors:  C A Evans; J Jellis; S P Hughes; D G Remick; J S Friedland
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

Review 4.  The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective.

Authors:  C J Kirkpatrick; F Bittinger; C L Klein; S Hauptmann; B Klosterhalfen
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

5.  Low-dose exposure of C57BL/6 mice to burkholderia pseudomallei mimics chronic human melioidosis.

Authors:  Laura Conejero; Natasha Patel; Melanie de Reynal; Sara Oberdorf; Joanne Prior; Philip L Felgner; Richard W Titball; Francisco J Salguero; Gregory J Bancroft
Journal:  Am J Pathol       Date:  2011-05-05       Impact factor: 4.307

6.  CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines.

Authors:  J E Crabtree; S M Farmery; I J Lindley; N Figura; P Peichl; D S Tompkins
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

7.  Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density.

Authors:  H D Foss; H Herbst; S Gottstein; G Demel; I Araujó; H Stein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.

Authors:  Surasakdi Wongratanacheewin; Wannapa Kespichayawattana; Pakamas Intachote; Sathit Pichyangkul; Rasana W Sermswan; Arthur M Krieg; Stitaya Sirisinha
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Production of interleukin-27 by human neutrophils regulates their function during bacterial infection.

Authors:  Darawan Rinchai; Prasong Khaenam; Chidchamai Kewcharoenwong; Surachat Buddhisa; Rungnapa Pankla; Damien Chaussabel; Gregory J Bancroft; Ganjana Lertmemongkolchai
Journal:  Eur J Immunol       Date:  2012-10-25       Impact factor: 5.532

10.  Innate immune responses of pulmonary epithelial cells to Burkholderia pseudomallei infection.

Authors:  Siew Hoon Sim; Yichun Liu; Dongling Wang; Vidhya Novem; Suppiah Paramalingam Sivalingam; Tuck Weng Thong; Eng Eong Ooi; Gladys Tan
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.